Related Experiment Video
Updated: Mar 22, 2026
09:38
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
14.5K
Platelet-Mediated Thrombosis: From Bench to Bedside
Paul A Gurbel1, Young-Hoon Jeong2, Eliano P Navarese2
1From the Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Fairfax, VA (P.A.G., E.P.N., U.S.T.); and Clinical Trial Center, Gyeongsang National University Hospital, Gyeongsangnam-do, Korea (Y.-H.J.). Paul.gurbel@inova.org.
Circulation Research
|April 30, 2016
Summary
Platelet function testing guides antiplatelet therapy in high-risk coronary artery disease. Current evidence does not support personalized therapy based on these tests for reducing ischemic events.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Platelets are crucial in thrombosis and ischemic events in high-risk coronary artery disease.
- Dual antiplatelet therapy (aspirin and P2Y12 inhibitor) is standard care.
- Point-of-care platelet function tests (PFTs) are increasingly used.
Purpose of the Study:
- To evaluate the clinical utility of PFTs in guiding antiplatelet therapy.
- To assess the relationship between PFT results and clinical outcomes.
- To determine if personalized antiplatelet therapy based on PFTs reduces ischemic events.
Main Methods:
- Review of observational studies and prospective randomized trials on PFTs.
- Analysis of the association between PFT results and clinical events (ischemia, bleeding).
- Exploration of the therapeutic window concept for P2Y12 receptor reactivity.
Main Results:
- Observational studies show a link between PFT results and clinical events.
- Prospective trials have not demonstrated that PFT-guided personalized therapy reduces ischemic events.
- Limitations exist in current trial designs and the proposed therapeutic window concept.
Conclusions:
- Strong prospective evidence supporting PFT-guided personalized antiplatelet therapy is lacking.
- Clinical decisions rely on observational data and the established role of platelet physiology.
- Further research is needed to clarify the role of PFTs in managing antiplatelet therapy.
Related Concept Videos
01:22Formation of the Platelet Plug
10.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.5K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
01:29Venous Thrombosis III: Interprofessional Care
459
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
459
01:18Structure and Function of Platelets
4.5K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.5K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
15.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.1K